Showing results (41-50 of 130) with videos related to

Sort By:
Pageof 13
Cancer Chemotherapy and Pharmacology|August 4, 2009
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinomaPaul Haluska, Frank Worden, David Olmos, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2024
Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancerGuilhem Roubaud, Gerhardt Attard, Martin Boegemann, et al.
Cancer Chemotherapy and Pharmacology|November 12, 2010
Clinical benefit of early phase clinical trial participation for advanced sarcoma patientsRobin L Jones, David Olmos, Khin Thway, et al.
European Urology|September 4, 2016
DNA Repair in Prostate Cancer: Biology and Clinical ImplicationsJoaquin Mateo, Gunther Boysen, Christopher E Barbieri, et al.
Plos One|January 11, 2014
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trialsDavid J Pinato, Chara Stavraka, Michael J Flynn, et al.
The Lancet. Oncology|April 13, 2026
Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trialAlicia K Morgans, Kunhi Parambath Haresh, Mindaugas Jievaltas, et al.
Journal of Endovascular Therapy : an Official Journal of the International Society of Endovascular Specialists|April 1, 2025
Comparative Long-Term Outcomes of Drug-Coated Balloons Alone Versus Combined Treatment with Rotational Atherectomy in the Treatment of Femoropopliteal Artery In-Stent RestenosisVicente Molina Nácher, José C Roselló Paredes, Laura Gálvez Núñez, et al.
European Urology|January 15, 2013
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomogramsAurelius Omlin, Carmel Pezaro, Deborah Mukherji, et al.
European Urology|August 10, 2021
Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate CancerDavid Lorente, Casilda Llacer, Rebeca Lozano, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2010
A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attritionAndre T Brunetto, Joo Ern Ang, David Olmos, et al.
Pageof 13